Moderna jumps as investors refocus on upcoming ESCMID revaccination vaccine data
Moderna shares rose after the company said it will present late-breaking revaccination data for its investigational flu vaccine (mRNA-1010) and its RSV vaccine (mRESVIA) at ESCMID 2026 in Munich on April 17–21, 2026. The update revived near-term catalyst focus ahead of the conference after a choppy stretch for the stock.
1. What’s moving the stock today
Moderna (MRNA) is trading higher as investors react to a fresh near-term catalyst: the company’s plan to present late-breaking revaccination data for its investigational seasonal influenza vaccine (mRNA-1010) and for its RSV vaccine (mRESVIA) at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress. The meeting runs April 17–21, 2026, putting a defined date on upcoming clinical updates that traders can position around.
2. Why this catalyst matters now
The ESCMID presentations arrive at a sensitive moment for Moderna’s narrative: the company is trying to expand beyond COVID into a broader respiratory franchise while also advancing oncology programs. Any supportive revaccination data can reinforce confidence in product durability and repeat-use performance—key attributes for seasonal markets—while also potentially improving sentiment after prior regulatory uncertainty around the U.S. filing for mRNA-1010.
3. What to watch next
The immediate focus is the late-breaking oral presentations during April 17–21, 2026. Traders will be watching for details on immunogenicity, safety/tolerability, and how performance looks in revaccination settings, plus any commentary that clarifies next regulatory steps for the flu program and demand trajectory for mRESVIA.